Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Stopped early · Not applicable

Conditions studied: Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy

In brief

This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber implantable cardioverter defibrillators (ICD) systems. Patients will be randomly assigned to either personalized accelerated pacing (using the myPACE+ algorithm with mono-fractional exponent) or usual care groups. At baseline and after 3 months of pacing all patients will undergo a CPET, echocardiogram, blood work for NT-proBNP levels and complete the KCCQ-OSS and HCMSQ, questionnaires. The investigator team hypothesizes that personalized accelerated pacing will be safe and improve symptoms and heart-failure related quality of life, physical activity, pVO2, biomarkers (i.e. NT-proBNP), diastolic parameters and cardiac structure.

Key facts

Study ID

NCT06775886

Run by

Montefiore Medical Center

People needed

1

Starts

2025-10-02

Expected to finish

2025-10-23

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non obstructive HCM: Left Ventricular Outflow Tract (LVOT) gradient <30mmHg at rest and with provocation
• Left ventricular ejection fraction (LVEF) ≥50%
• New York Heart Association (NYHA II-III) symptoms
• Normal intrinsic conduction system
• Suitable dual-chamber implantable cardioverter defibrillators (ICD) system

You may not qualify if…

• Pregnancy
• LVEF <50%
• LVOT gradient > 30mmHg at rest or with provocation
• Prolonged PR > 250ms
• Baseline RV-pacing burden of > 1% more than moderate valvular stenosis or regurgitation
• Aortic valve replacement in the past one year
• Significant primary pulmonary disease on home oxygen
• Uncontrolled hypertension as defined by BP >160/100 mmHg on two measurements ≥15 minutes apart

Where it is running

• Montefiore Medical Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.